Skip to main content

Table 1 Demographics and Baseline Characteristics of Participants in C601/C602 and PATH for PWS

From: Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study

 

C601/C602

(N = 114)

PATH for PWS

(N = 229)

Age, years mean ± SD

13.1 ± 6.17

17.9 ± 9.49

Race, n (%)

  

White

98 (86.0%)

185 (80.8%)

Black or African American

6 (5.3%)

6 (2.6%)

Asian

1 (0.9%)

4 (1.7%)

American Indian or Alaska Native

0 (0.0%)

0 (0.0%)

Native Hawaiian or Other Pacific Islander

0 (0.0%)

0 (0.0%)

Other

2 (1.8%)

9 (3.9%)

Multiple

7 (6.1%)

22 (9.6%)

Not Reported

0 (0.0%)

3 (1.3%)

Sex, n (%)

  

Male

48 (42.1%)

110 (48.0%)

Female

66 (57.9%)

119 (52.0%)

PWS genetic subtype n (%)

  

Deletion

71 (62.3%)

113 (49.3%)

Non-deletion

43 (37.7%)

82 (35.8%)

Not reported

0 (0.0%)

34 (14.8%)

Weight, kg mean ± SD

60.3 ± 29.69

66.7 ± 26.72

BMI, mean ± SD

26.8 ± 9.3

28.9 ± 9.76

Baseline HQ-CT, mean ± SD

21.3 ± 6.73

18.2 ± 4.99

Growth hormone use n (%)

  

Yes (at both visits)

95 (83.3%)

130 (56.8%)

No (at both visits)

19 (16.7%)

87 (38%)

Only at baseline

0 (0.0%)

6 (2.6%)

Only at 6 months

0 (0.0%)

6 (2.6%)

PWSP Domain

N = 103

N = 167

Aggressive Behaviors mean ± SD

7.5 ± 3.81

8.9 ± 4.18

Anxiety mean ± SD

12.9 ± 5.29

13.7 ± 5.05

Compulsivity mean ± SD

12.0 ± 4.85

12.3 ± 4.48

Depression mean ± SD

3.6 ± 2.27

3.8 ± 2.25

Disorder Thinking mean ± SD

4.3 ± 3.33

4.5 ± 3.05

Rigidity/Irritability mean ± SD

10.9 ± 5.33

12.0 ± 5.25